CollPlant Biotechnologies (NASDAQ: CLGN) deputy CEO details option and RSU stakes

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd executive Rotem Eran, the Deputy CEO and CFO, filed an initial statement of beneficial ownership showing equity awards in the company. The filing lists several option grants to purchase Ordinary Shares, along with a block of restricted share units.

The holdings include options over 80,000 Ordinary Shares at an exercise price of $6.3900 per share expiring on January 27, 2032, 45,000 shares at $4.0200 expiring on December 26, 2027, 9,000 shares at $4.0200 expiring on May 18, 2028, and 52,707 shares at $6.3900 expiring on May 26, 2030, all reported as fully vested and exercisable where noted. Eran also holds 60,000 restricted share units, of which 26,250 are vested and 33,750 are scheduled to vest in nine equal quarterly installments from June 8, 2026 through June 8, 2028, subject to continued service.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Rotem Eran

Role Deputy CEO and CFO

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 45,000 shares (Direct); Restricted Share Units — 60,000 shares (Direct)

Footnotes (1)

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee. Of the restricted share units reported herein, 26,250 units are vested, and the remaining 33,750 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date. Fully vested and exercisable.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/18/2026 - 10:09 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rotem Eran

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Deputy CEO and CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units(1)	60,000(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(3)	12/26/2018	12/26/2027	Ordinary Shares	45,000(3)	$4.02	D
Options to Purchase Ordinary Shares(1)(3)	05/18/2016	05/18/2028	Ordinary Shares	9,000(3)	$4.02	D
Options to Purchase Ordinary Shares(1)(3)	05/26/2021	05/26/2030	Ordinary Shares	52,707(3)	$6.39	D
Options to Purchase Ordinary Shares(1)(3)	01/27/2023	01/27/2032	Ordinary Shares	80,000(3)	$6.39	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.

2. Of the restricted share units reported herein, 26,250 units are vested, and the remaining 33,750 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

3. Fully vested and exercisable.

	/s/ Eran Rotem	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does CollPlant Biotechnologies (CLGN) deputy CEO Rotem Eran report in this Form 3?

Rotem Eran reports his initial beneficial ownership in CollPlant through stock options and restricted share units. The filing lists multiple option grants on Ordinary Shares and a separate block of RSUs, detailing exercise prices, expiration dates, vesting status, and overall equity exposure as an executive.

How many stock options does Rotem Eran hold in CollPlant Biotechnologies (CLGN)?

The Form 3 shows several option positions to purchase Ordinary Shares, including 80,000 shares at $6.3900, 45,000 shares at $4.0200, 9,000 shares at $4.0200, and 52,707 shares at $6.3900. Each grant has its own stated expiration date and is reported as directly owned.

What restricted share unit (RSU) holdings are reported for Rotem Eran at CollPlant (CLGN)?

Eran reports 60,000 restricted share units. According to the filing, 26,250 RSUs are already vested, while the remaining 33,750 are scheduled to vest in nine equal quarterly installments between June 8, 2026 and June 8, 2028, contingent on his continued service with CollPlant.

How do the vesting terms work for Rotem Eran’s RSUs at CollPlant Biotechnologies (CLGN)?

The vesting schedule divides 33,750 unvested RSUs into nine equal quarterly tranches. These installments begin on June 8, 2026 and end on June 8, 2028. Each tranche vests only if Eran continues to serve CollPlant through the applicable vesting date, according to the disclosure.

What are the exercise prices and expirations of Rotem Eran’s options in CollPlant (CLGN)?

The options carry exercise prices of $4.0200 and $6.3900 per Ordinary Share. Expiration dates range from December 26, 2027 and May 18, 2028 to later dates such as May 26, 2030 and January 27, 2032, defining the periods during which the options can be exercised.